In the cancer setting, comparable levels of antigen loading were observed in the lung and the medLN (Fig. S7A-B), but while cDC upregulated CD80 and CD86 in response to both BrightFlu antigen uptake, only CD86 was upregulated in the cancer setting (Fig. 2J). This evidence concerns the gene CD86 and cancer.